Table 2.
Diagnostic values of the screening tests for unilateral PA in the development cohort.
| AUC ROC (95% CI) | Cut-Off Value | SENS | SPEC | PPV | NPV | ACC | p-Value | |
|---|---|---|---|---|---|---|---|---|
| Adrenal nodule on CT | 0.780 (0.714–0.846) |
≥6 mm | 71% | 85% | 90% | 62% | 76% | <0.001 |
| Serum potassium | 0.635 (0.555–0.716) |
<3.6 mmol/L | 60% | 67% | 76% | 49% | 63% | 0.005 |
| ARR baseline | 0.692 (0.616–0.768) |
≥100 ng/dL/(ng/mL/h) | 53% | 85% | 86% | 51% | 65% | <0.001 |
| PAC baseline | 0.648 (0.569–0.727) |
≥280 ng/L | 51% | 70% | 75% | 45% | 56% | 0.01 |
| PAC increase after PST | 0.582 (0.501–0.663) |
<30% | 31% | 85% | 79% | 41% | 51% | 0.05 |
| PAC after SIT | 0.682 (0.606–0.757) |
≥165 ng/L | 60% | 76% | 82% | 52% | 66% | <0.001 |
ACC—accuracy; ARR—aldosterone-to-renin ratio; AUC-ROC—area under the receiver operating characteristic curve; CI—confidence interval; CT—computed tomography; NPV—negative predictive value; PAC—plasma aldosterone concentration; PPV—positive predictive value; PST—postural stimulation test; SENS—sensitivity; SIT—saline infusion test; SPEC—specificity.